Render Target: SSR
Render Timestamp: 2025-01-23T18:59:02.848Z
Commit: da7e4f2f0d1aed1f1f8e20e4e2ecab8f33cbd595
XML generation date: 2024-09-30 01:54:37.887
Product last modified at: 2025-01-01T09:05:30.772Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

BSCL2/Seipin (D3W8C) Rabbit mAb #23846

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 50
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:100

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    BSCL2/Seipin (D3W8C) Rabbit mAb recognizes endogenous levels of total BSCL2/Seipin protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Glu383 of human BSCL2 protein.

    Background

    Seipin/BSCL2 is a homo-oligomeric membrane protein at the endoplasmic reticulum lipid droplet junction (1). Studies have demonstrated that Seipin/BSCL2 plays an important role in adipogenesis, lipid droplet homeostasis, liposis, brain development, and spermatogenesis. However, the exact function of BSCL2/Seipin is still not clear (2-5). BSCL2/Seipin is mutated in several human diseases, including Berardinelli-Seip congenital lipodystrophy, an autosomal recessive disorder characterized by a near absence of adipose tissues, severe insulin resistance, hypertriglyceridemia, hepatic steatosis, and early onset of diabetes (6-8).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.